108 related articles for article (PubMed ID: 7747773)
1. Tumors in Rubinstein-Taybi syndrome.
Miller RW; Rubinstein JH
Am J Med Genet; 1995 Mar; 56(1):112-5. PubMed ID: 7747773
[TBL] [Abstract][Full Text] [Related]
2. Pilomatrixomas in Rubinstein-Taybi syndrome.
Masuno M; Imaizumi K; Ishii T; Kuroki Y; Baba N; Tanaka Y
Am J Med Genet; 1998 Apr; 77(1):81-2. PubMed ID: 9557902
[No Abstract] [Full Text] [Related]
3. Cardiac abnormalities in the Rubinstein-Taybi syndrome.
Stevens CA; Bhakta MG
Am J Med Genet; 1995 Nov; 59(3):346-8. PubMed ID: 8599359
[TBL] [Abstract][Full Text] [Related]
4. Genetic Predisposition to Sarcoma: What Should Clinicians Know?
Vagher J; Mehrhoff CJ; Florou V; Maese LD
Curr Treat Options Oncol; 2024 May; ():. PubMed ID: 38713268
[TBL] [Abstract][Full Text] [Related]
5. Shared etiology of Mendelian and complex disease supports drug discovery.
Lalagkas PN; Melamed RD
Res Sq; 2024 Apr; ():. PubMed ID: 38699347
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and management in Rubinstein-Taybi syndrome: first international consensus statement.
Lacombe D; Bloch-Zupan A; Bredrup C; Cooper EB; Houge SD; García-Miñaúr S; Kayserili H; Larizza L; Lopez Gonzalez V; Menke LA; Milani D; Saettini F; Stevens CA; Tooke L; Van der Zee JA; Van Genderen MM; Van-Gils J; Waite J; Adrien JL; Bartsch O; Bitoun P; Bouts AHM; Cueto-González AM; Dominguez-Garrido E; Duijkers FA; Fergelot P; Halstead E; Huisman SA; Meossi C; Mullins J; Nikkel SM; Oliver C; Prada E; Rei A; Riddle I; Rodriguez-Fonseca C; Rodríguez Pena R; Russell J; Saba A; Santos-Simarro F; Simpson BN; Smith DF; Stevens MF; Szakszon K; Taupiac E; Totaro N; Valenzuena Palafoll I; Van Der Kaay DCM; Van Wijk MP; Vyshka K; Wiley S; Hennekam RC
J Med Genet; 2024 May; 61(6):503-519. PubMed ID: 38471765
[TBL] [Abstract][Full Text] [Related]
7. Rubinstein-Taybi Syndrome: A Model of Epigenetic Disorder.
Van Gils J; Magdinier F; Fergelot P; Lacombe D
Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34202860
[TBL] [Abstract][Full Text] [Related]
8. Gene Signature Associated With Bromodomain Genes Predicts the Prognosis of Kidney Renal Clear Cell Carcinoma.
Lu J; Qian C; Ji Y; Bao Q; Lu B
Front Genet; 2021; 12():643935. PubMed ID: 34149798
[TBL] [Abstract][Full Text] [Related]
9. Pediatric Rhabdomyosarcoma: Epidemiology and Genetic Susceptibility.
Martin-Giacalone BA; Weinstein PA; Plon SE; Lupo PJ
J Clin Med; 2021 May; 10(9):. PubMed ID: 34065162
[TBL] [Abstract][Full Text] [Related]
10. Insights into the Role of the Microbiota and of Short-Chain Fatty Acids in Rubinstein-Taybi Syndrome.
Di Fede E; Ottaviano E; Grazioli P; Ceccarani C; Galeone A; Parodi C; Colombo EA; Bassanini G; Fazio G; Severgnini M; Milani D; Verduci E; Vaccari T; Massa V; Borghi E; Gervasini C
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33807238
[TBL] [Abstract][Full Text] [Related]
11. Ultrasound 2-D and 3-D diagnosis of Rubinstein-Taybi syndrome in a 21-week-old fetus.
D'Ambrosi F; Ronzoni L; Villa R; De Marinis S; Cetera GE; Soldavini CM; Ferrazzi E
J Ultrasound; 2022 Jun; 25(2):301-304. PubMed ID: 32557407
[TBL] [Abstract][Full Text] [Related]
12. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.
Cheng Y; He C; Wang M; Ma X; Mo F; Yang S; Han J; Wei X
Signal Transduct Target Ther; 2019; 4():62. PubMed ID: 31871779
[TBL] [Abstract][Full Text] [Related]
13. Functional Interaction of BRCA1 and CREBBP in Murine Hematopoiesis.
Holmstrom SR; Wijayatunge R; McCrum K; Mgbemena VE; Ross TS
iScience; 2019 Sep; 19():809-820. PubMed ID: 31499338
[TBL] [Abstract][Full Text] [Related]
14. Preferential sensitivity to HDAC inhibitors in tumors with CREBBP mutation.
Hellwig M; Merk DJ; Lutz B; Schüller U
Cancer Gene Ther; 2020 May; 27(5):294-300. PubMed ID: 31068675
[TBL] [Abstract][Full Text] [Related]
15. Rubinstein-Taybi syndrome in a Saudi boy with distinct features and variants in both the CREBBP and EP300 genes: a case report.
Al-Qattan MM; Jarman A; Rafique A; Al-Hassnan ZN; Al-Qattan HM
BMC Med Genet; 2019 Jan; 20(1):12. PubMed ID: 30635043
[TBL] [Abstract][Full Text] [Related]
16. De novo FBXO11 mutations are associated with intellectual disability and behavioural anomalies.
Fritzen D; Kuechler A; Grimmel M; Becker J; Peters S; Sturm M; Hundertmark H; Schmidt A; Kreiß M; Strom TM; Wieczorek D; Haack TB; Beck-Wödl S; Cremer K; Engels H
Hum Genet; 2018 May; 137(5):401-411. PubMed ID: 29796876
[TBL] [Abstract][Full Text] [Related]
17. Benign and malignant tumors in Rubinstein-Taybi syndrome.
Boot MV; van Belzen MJ; Overbeek LI; Hijmering N; Mendeville M; Waisfisz Q; Wesseling P; Hennekam RC; de Jong D
Am J Med Genet A; 2018 Mar; 176(3):597-608. PubMed ID: 29359884
[TBL] [Abstract][Full Text] [Related]
18. Rubinstein-Taybi Syndrome Associated with Pituitary Macroadenoma: A Case Report.
Olyaei Y; Sarmiento JM; Bannykh SI; Drazin D; Naruse RT; King W
Cureus; 2017 Apr; 9(4):e1151. PubMed ID: 28503387
[TBL] [Abstract][Full Text] [Related]
19. A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes.
Scollon S; Anglin AK; Thomas M; Turner JT; Wolfe Schneider K
J Genet Couns; 2017 Jun; 26(3):387-434. PubMed ID: 28357779
[TBL] [Abstract][Full Text] [Related]
20. CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.
Dixon ZA; Nicholson L; Zeppetzauer M; Matheson E; Sinclair P; Harrison CJ; Irving JA
Haematologica; 2017 Apr; 102(4):736-745. PubMed ID: 27979926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
